PT  - JOURNAL ARTICLE
AU  - Pal, Prodipto
AU  - Khan, Zanobia
TI  - <em>ROS1-1</em>
AID  - 10.1136/jclinpath-2016-204244
DP  - 2017 Dec 01
TA  - Journal of Clinical Pathology
PG  - 1001--1009
VI  - 70
IP  - 12
4099  - http://jcp.bmj.com/content/70/12/1001.short
4100  - http://jcp.bmj.com/content/70/12/1001.full
SO  - J Clin Pathol2017 Dec 01; 70
AB  - ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%–2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal carcinoma and in spitzoid neoplasms, glioblastoma and inflammatory myofibroblastic tumours. The ROS1 gene fusion undergoes constitutive activation, regulates cellular proliferation and is implicated in carcinogenesis. ROS1 fusions can be detected by fluorescence in situ hybridisation, real-time PCR, sequencing-based techniques and immunohistochemistry-based methods in clinical laboratories. The small molecule tyrosine kinase inhibitor, crizotinib has been shown to be an effective inhibitor of ROS1 and has received Food and Drug Administration approval for treatment of advanced NSCLC. The current review is an update on the clinical findings and detection methods of ROS1 in clinical laboratories in NSCLC and other tumours.